DMG MORI AKTIENGESELLSCHAFT

  • WKN: 587800
  • ISIN: DE0005878003
  • Land: Deutschland

Nachricht vom 13.03.2017 | 15:01

DMG MORI AKTIENGESELLSCHAFT: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DMG MORI AKTIENGESELLSCHAFT

13.03.2017 / 15:01
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
DMG MORI AKTIENGESELLSCHAFT
Gildemeisterstraße 60
33689 Bielefeld
Germany

2. Reason for notification
X Acquisition/disposal of shares with voting rights
X Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Name: City and country of registered office:
Bank of America Corporation Wilmington, DE
United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
N/A

5. Date on which threshold was crossed or reached
03 March 2017

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
total of both in %
(7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation 0.00 % 0.04 % 0.04 % 78817994
Previous notification 0.26 % 5.57 % 5.84 % /

7. Notified details of the resulting situation
a. Voting rights attached to shares (Sec.s 21, 22 WpHG)
ISIN absolute in %
  direct
(Sec. 21 WpHG)
indirect
(Sec. 22 WpHG)
direct
(Sec. 21 WpHG)
indirect
(Sec. 22 WpHG)
N/A % %
Total %

b.1. Instruments according to Sec. 25 para. 1 No. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
N/A %
    Total %

b.2. Instruments according to Sec. 25 para. 1 No. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
Swaps 16.04.2018 N/A Cash 6755 0.009 %
Swaps 15.09.2017 N/A Cash 21830 0.028 %
      Total 28585 0.036 %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least held 3% or more) % of voting rights through instruments (if at least held 5% or more) Total of both (if at least held 5% or more)
Bank of America Corporation N/A % N/A % N/A %
NB Holdings Corporation N/A % N/A % N/A %
Merrill Lynch International Incorporated N/A % N/A % N/A %
Merrill Lynch Group Holdings I, L.L.C. N/A % N/A % N/A %
BofAML Jersey Holdings Limited N/A % N/A % N/A %
BofAML EMEA Holdings 1 Limited N/A % N/A % N/A %
BofAML EMEA Holdings 2 Limited N/A % N/A % N/A %
ML UK Capital Holdings Limited N/A % N/A % N/A %
Merrill Lynch International N/A % N/A % N/A %
Bank of America Corporation N/A % N/A % N/A %
NB Holdings Corporation N/A % N/A % N/A %
BAC North America Holding Company N/A % N/A % N/A %
BANA Holding Corporation N/A % N/A % N/A %
Bank of America, National Association N/A % N/A % N/A %

9. In case of proxy voting according to Sec. 22 para. 3 WpHG

Date of general meeting:
Holding position after general meeting: % (equals voting rights)

10. Other explanatory remarks:
 



13.03.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

PSI Software AG

Original-Research: PSI AG (von First Berlin Equity Research GmbH): Hinzufügen

06. Dezember 2021